National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels

Majority of survey respondents call for new treatments to help manage phosphorus levels

WALTHAM, Mass. and NEW YORK, Nov. 4, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX) in partnership with the National Kidney Foundation (NKF), today announced results from a survey of patients with chronic kidney disease (CKD) on dialysis conducted to better understand patients' experience managing serum phosphorus levels. The survey found that more than 80% of respondents struggle to manage their serum phosphorus levels, with more than 90% citing a need for new treatment options.